Cambridge, Mass. – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Beam Therapeutics is the first company to pursue development of new therapies using base editing technology, which enables single-letter editing of DNA and RNA. Beam launched in May 2018 with $87 million in Series A funding led by F-Prime Capital Partners and ARCH Venture Partners. The company’s founders include three of the world’s leading CRISPR experts: David Liu, Ph.D., of Harvard University; J. Keith Joung, M.D., Ph.D., of Massachusetts General Hospital and Harvard Medical School; and Feng Zhang, Ph.D., of the Broad Institute of MIT and Harvard.
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s16thannual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotechprovides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotechevaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotechis the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotechfor an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Beam Therapeutics
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Headquartered in Cambridge, Massachusetts, the company is backed by F-Prime Capital Partners and ARCH Venture Partners, two of the world’s leading biotech venture capital firms. For additional information, visit www.BeamTx.com.